The worst-case scenario for the US Food and Drug Administration and industry stakeholders is no user fee reauthorization by 1 October, when the current programs expire, but all may not be lost should that day pass without enacted legislation.
Stakeholders believe the user fee programs eventually will be renewed. The bill has long been considered must-pass legislation, since it supports thousands of jobs at the FDA that help drug...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?